Table 1 Study descriptive characteristics
Characteristic | Controls | Cases | Total | p-value |
|---|---|---|---|---|
n (col %) | n (col %) | n (col %) | ||
Gender | ||||
Female | 151(59.2) | 28(32.9) | 179(52.6) | < 0.001 |
Male | 104(40.8) | 57(67.1) | 161(47.4) | |
Total | 255(100) | 85(100) | 340(100) | |
Type of second-line drug | ||||
lopinavir | 241(94.5) | 71(83.5) | 312(91.8) | 0.001 |
Atazanavir | 8(3.1) | 4(4.7) | 12(3.5) | |
Other PIµ | 6(2.4) | 10(11.8) | 16(4.7) | |
Total | 255(100) | 85(100) | 340(100) | |
TB treatment§ | ||||
No | 246(97.2) | 71(83.5) | 317(93.8) | < 0.001 |
YES | 7(2.8) | 14(16.5) | 21(6.2) | |
Total | 253(100) | 85(100) | 338(100) | |
Year of ART initiation | ||||
Before 2001 | 7(2.7) | 23(27.1) | 30(8.8) | < 0.001 |
2001–2005 | 170(66.7) | 41(48.2) | 211(62.1) | |
2006–2010 | 64(25.1) | 19(22.4) | 83(24.4) | |
2011–2015 | 14(5.5) | 2(2.4) | 16(4.7) | |
Total | 255(100) | 85(100) | 340(100) | |
Type of first-line drug | ||||
NNRTI based | 217(85.1) | 66(77.6) | 283(83.2) | 0.111 |
NON-NNRTI∞ | 38(14.9) | 19(22.4) | 57(16.8) | |
Total | 255(100) | 85(100) | 340(100) | |
Other comorbidities § | ||||
No | 226(89.3) | 76(89.4) | 302(89.3) | 0.983 |
Yes | 27(10.7) | 9(10.6) | 36(10.7) | |
Total | 253(100) | 85(100) | 338(100) | |
Age at start of 2nd line: median (IQR) | ||||
38(32–46) | 38(31–46) | 38(32–46) | 0.300 | |
CD4 at start of 2nd line: median (IQR) | ||||
130(62–250) | 68.5(18–181) | 115(41–234) | 0.079 | |
VL at start of 2nd line: median (IQR)¥ | ||||
43,005.5(13,645.5–135,553.5) | 233,700(65,985.5–601,989) | 67,965(18,846.5–189,160) | < 0.001 | |
Duration on 1st line: median (IQR) | ||||
4 (2 – 5) | 3 (2–6) | 3 (2–5) | 0.210 | |